Phio Pharmaceuticals (PHIO) Income from Continuing Operations (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Income from Continuing Operations came in at 4006000.0 in Q1 2026, down 146.98% YoY from 8527207.35 in Q1 2025, and down 67.47% on a QoQ basis from 2392000.0 in Q3 2025.
Phio Pharmaceuticals (PHIO) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Income from Continuing Operations data on file, last reported at 4006000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 146.98% year-over-year to 4006000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10329000.0 (down 52.53% YoY) and the FY2024 annual result came in at 7703000.0, up 42.4% from the prior year.
- Income from Continuing Operations slipped to 4006000.0 in Q1 2026, from 2392000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1524000.0 in Q3 2024 to a low of 4006000.0 in Q1 2026.
- A 5-year average of 2504187.5 and a median of 2473500.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 45.78% — and 2026, when it plunged 146.98%.
- Tracing PHIO's Income from Continuing Operations over 5 years: stood at 2764000.0 in 2022, then surged by 34.66% to 1806000.0 in 2023, then gained by 5.09% to 1714000.0 in 2024, then tumbled by 39.56% to 2392000.0 in 2025, then sank by 67.47% to 4006000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4006000.0 (Q1 2026), 2392000.0 (Q3 2025), and 2309000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | -4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.14 Mn |
| Mar 31, 2026 | -4.01 Mn |
| Sep 30, 2025 | -2.39 Mn |
| Jun 30, 2025 | -2.31 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | -1.71 Mn |
| Sep 30, 2024 | -1.52 Mn |
| Jun 30, 2024 | -1.91 Mn |
| Mar 31, 2024 | -2.16 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | -2.81 Mn |
| Jun 30, 2023 | -2.58 Mn |
| Mar 31, 2023 | -3.64 Mn |
| Dec 31, 2022 | -2.76 Mn |
| Sep 30, 2022 | -3.61 Mn |
| Jun 30, 2022 | -2.56 Mn |
| Mar 31, 2022 | -2.67 Mn |
| Dec 31, 2021 | -3.47 Mn |
| Sep 30, 2021 | -3.78 Mn |
| Jun 30, 2021 | -2.72 Mn |